Order Article Reprints

Petrakis I, Kontogiorgis C, Nena E, Delimpasi S, Loutsidi NE, Spanoudakis E, Intzes S, Misidou C, Symeonidou M, Giannakoulas N, et al. Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study. Cancers. 2023; 15(24):5846. https://doi.org/10.3390/cancers15245846

Petrakis, Ioannis, Christos Kontogiorgis, Evangelia Nena, Sosana Delimpasi, Natasa E. Loutsidi, Emmanouil Spanoudakis, Stergios Intzes, Christina Misidou, Marianthi Symeonidou, Nikolaos Giannakoulas, and et al. 2023. "Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study" Cancers 15, no. 24: 5846. https://doi.org/10.3390/cancers15245846

Petrakis, I., Kontogiorgis, C., Nena, E., Delimpasi, S., Loutsidi, N. E., Spanoudakis, E., Intzes, S., Misidou, C., Symeonidou, M., Giannakoulas, N., Constantinidis, T. C., & Terpos, E. (2023). Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study. Cancers, 15(24), 5846. https://doi.org/10.3390/cancers15245846